BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 10993101)

  • 1. Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation.
    Toki T; Kubota J; Lu X; Nakayama K
    Acta Obstet Gynecol Scand; 2000 Sep; 79(9):771-6. PubMed ID: 10993101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of CA19-9 for endometriosis].
    Watanabe J; Johboh T; Hata H; Kuramoto H
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):155-61. PubMed ID: 2313144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
    Kataoka T; Watanabe Y; Hoshiai H
    J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
    Yang XQ; Yan L; Chen C; Hou JX; Li Y
    Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A resected case of intralobar pulmonary sequestration with increased serum tumor markers, CA19-9, CA125 and NCC-ST-439].
    Nakamura H; Katsumi T; Nagata S; Saito M; Konaka C; Kato H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Dec; 35(12):1425-29. PubMed ID: 9567093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal cyst producing CA19-9 and CA125.
    Goto T; Maeshima A; Oyamada Y; Kato R
    Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):448-50. PubMed ID: 20008896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumour markers in patients with chronic kidney disease.
    Xiaofang Y; Yue Z; Xialian X; Zhibin Y
    Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
    Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
    Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma.
    Takeshima N; Shimizu Y; Umezawa S; Hirai Y; Chen JT; Fujimoto I; Yamauchi K; Hasumi K
    Gynecol Oncol; 1994 Sep; 54(3):321-6. PubMed ID: 8088608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
    Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
    Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9.
    Gao YC; Yuan ZB; Yang YD; Lu HK
    Scand J Clin Lab Invest; 2007; 67(7):741-7. PubMed ID: 17852813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple epithelial cysts of the spleen and on the splenic capsule, and high serum levels of CA19-9, CA125 and soluble IL-2 receptor.
    Hashimoto T; Sugino T; Fukuda T; Hoshi N; Ogura G; Watanabe K; Satoh Y; Hasegawa T; Ohishi A; Haga J; Miyata M; Suzuki T
    Pathol Int; 2004 May; 54(5):349-54. PubMed ID: 15086840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.